CYP3A4 and tuberculosis: Additionally, Wang discussed the usage of Paxlovid, an antiviral therapeutic for COVID-19 treatment, and emphasized its contraindication in patients receiving rifampicin, one of the first-line agents for TB treatment, due to drug interactions as Paxlovid is a strong cytochrome P450 3A4 inhibitor.